Variation in Use of Anti-SARS-CoV-2 Monoclonal Antibody Therapies by Social Vulnerability and Urbanicity
Link
Description
Examines the variation in the use of the first two monoclonal antibody therapies for COVID-19 from November 2020 through March 2021. Presents data on the demographic characteristics of monoclonal antibody recipients and social vulnerability indices. Includes a discussion of the use of this therapy by urbanicity and density of primary care physicians.
Author(s)
Allison Kolbe
Date
12/2021
Type
Document
Organization
HHS Office of the Assistant Secretary for Planning and Evaluation
Tagged as
Access · COVID-19 · Health disparities · Specialty care · Statistics and data
Related Content
Organizations (1)
- HHS Office of the Assistant Secretary for Planning and Evaluation, view details